Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Biomea Fusion has raised $25.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Biomea Fusion's investors include Cormorant Asset Management, Janus Henderson Investors, RTW Investments, Rock Springs Capital, Aisling Capital.
Biomea Fusion is headquartered in Redwood City, United States.
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Biomea Fusion is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Biomea Fusion — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/biomea-fusion. Accessed July 20, 2026.
VCBacked. (2025). Biomea Fusion — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/biomea-fusion
{{cite web |title=Biomea Fusion — Funding & Investors |url=https://www.vcbacked.co/company/biomea-fusion |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated